DK2989203T3 - Syntetisk bibliotek for specifikke bindingsmolekyler - Google Patents

Syntetisk bibliotek for specifikke bindingsmolekyler Download PDF

Info

Publication number: DK2989203T3
Authority: DK; Denmark
Prior art keywords: specific binding; binding molecules; synthetic library; library; synthetic
Prior art date: 2013-04-23

Application number

DK14718999.7T

Other languages

English (en)

Inventor

Caroline Jane Barelle

William James Jonathan Finlay

Alfredo Darmanin-Sheehan

Andrew Justin Radcliffe Porter

Original Assignee

The Univ Court Of The Univ Of Aberdeen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-23

Filing date

2014-04-23

Publication date

2020-02-17

2014-04-23 Application filed by The Univ Court Of The Univ Of Aberdeen filed Critical The Univ Court Of The Univ Of Aberdeen

2020-02-17 Application granted granted Critical

2020-02-17 Publication of DK2989203T3 publication Critical patent/DK2989203T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Virology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Epidemiology (AREA)
Crystallography & Structural Chemistry (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)

DK14718999.7T 2013-04-23 2014-04-23 Syntetisk bibliotek for specifikke bindingsmolekyler DK2989203T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361815043P	2013-04-23	2013-04-23
PCT/EP2014/058251 WO2014173959A2 (en)	2013-04-23	2014-04-23	Synthetic library of specific binding molecules

Publications (1)

Publication Number	Publication Date
DK2989203T3 true DK2989203T3 (da)	2020-02-17

Family

ID=50543598

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14718999.7T DK2989203T3 (da)	2013-04-23	2014-04-23	Syntetisk bibliotek for specifikke bindingsmolekyler

Country Status (11)

Country	Link
US (3)	US10472410B2 (da)
EP (3)	EP3683312B1 (da)
JP (2)	JP6591964B2 (da)
KR (2)	KR102320189B1 (da)
CN (2)	CN105492610B (da)
AU (3)	AU2014257549B2 (da)
BR (2)	BR112015026729A2 (da)
CA (2)	CA2909921C (da)
DK (1)	DK2989203T3 (da)
RU (2)	RU2015146419A (da)
WO (2)	WO2014173975A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013167883A1 (en)	2012-05-07	2013-11-14	The University Court Of The University Of Aberdeen	Single domain binding molecule
EP3683312B1 (en)	2013-04-23	2022-09-07	Elasmogen Limited	Synthetic library of specific binding molecules
EP3160995A2 (en) *	2014-06-26	2017-05-03	Ossianix Inc.	Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
US11001640B2 (en) *	2014-11-03	2021-05-11	Merck Patent Gmbh	Methods for generating bispecific shark variable antibody domains and use thereof
WO2016077840A2 (en)	2014-11-14	2016-05-19	Ossianix, Inc.	TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
ITUB20151014A1 (it) *	2015-05-27	2016-11-27	Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro	Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
MX2018012472A (es)	2016-04-15	2019-08-12	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
CN107130300A (zh) *	2016-10-08	2017-09-05	深圳劲宇生物科技有限公司	一种dna编码分子库的合成方法及dna模板
US20200087390A1 (en)	2016-12-21	2020-03-19	Amgen Inc.	Anti-tnf alpha antibody formulations
CA3075367A1 (en)	2017-09-27	2019-04-04	Elasmogen Ltd	Specific binding molecules
US11180544B2 (en) *	2017-11-07	2021-11-23	City University Of Hong Kong	Method of producing antibody fragment
GB201721802D0 (en) *	2017-12-22	2018-02-07	Almac Discovery Ltd	Ror1-specific antigen binding molecules
US12351642B2 (en)	2018-09-14	2025-07-08	Ossianix, Inc.	TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
CN111197074B (zh) *	2018-11-20	2023-08-15	深圳华大生命科学研究院	条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
US20220130494A1 (en) *	2019-02-11	2022-04-28	Neal W. Woodbury	Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) *	2019-05-17	2019-07-03	Elasmogen Ltd	Conjugates
GB201908886D0 (en) *	2019-06-20	2019-08-07	Almac Discovery Ltd	Anthracycline derivatives
JP7765090B2 (ja) *	2020-05-01	2025-11-06	ユニバーシティオブピッツバーグ－オブザコモンウェルスシステムオブハイヤーエデュケイション	ナノボディ及びナノボディ親和性を同定するための組成物及び方法
CN112301431B (zh) *	2020-08-12	2023-01-31	华东理工大学	基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020154D0 (en) *	2020-12-18	2021-02-03	Almac Discovery Ltd	ROR1-specific variant antigen binding molecules
GB202020152D0 (en)	2020-12-18	2021-02-03	Elasmogen Ltd	Fast-track humanisation of specific binding molecules
WO2022212429A1 (en) *	2021-03-31	2022-10-06	Sachdev Sidhu	Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en)	2021-08-31	2023-03-01	Johann-Wolfgang-Goethe-Universität Frankfurt am Main	Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en)	2024-06-03	2024-07-17	Elasmogen Ltd	Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008419D0 (en)	2000-04-05	2000-05-24	Bioinvent Int Ab	A method for invitro molecular evolution of antibody function
CA2457636C (en)	2001-08-10	2012-01-03	Aberdeen University	Antigen binding domains
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US20050048617A1 (en) *	2003-08-18	2005-03-03	Medimmune, Inc.	Humanization of antibodies
EP1670932B1 (en) *	2003-08-27	2011-03-30	Proterec Ltd	Libraries of recombinant chimeric proteins
DK2330121T3 (da)	2004-06-02	2014-12-15	Adalta Pty Ltd	Bindingsdele baseret på haj-IgNar-domæner
MXPA06014075A (es) *	2004-06-03	2007-03-15	Novimmune Sa	Anticuerpos anti-cd3 y metodos de uso de los mismos.
WO2006003999A1 (ja) *	2004-07-05	2006-01-12	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
EP1869192B1 (en) *	2005-03-18	2016-01-20	MedImmune, LLC	Framework-shuffling of antibodies
WO2006099747A1 (en)	2005-03-25	2006-09-28	National Research Council Of Canada	Method for isolation of soluble polypeptides
AU2006249144B2 (en)	2005-05-18	2011-11-17	Ablynx Nv	Improved NanobodiesTM against Tumor Necrosis Factor-alpha
DK1915398T3 (da)	2005-07-18	2016-07-04	Amgen Inc	Humane anti-B7RP1 neutraliserende antistoffer
CN101646689A (zh)	2006-09-08	2010-02-10	埃博灵克斯股份有限公司	具有长半衰期的血清清蛋白结合蛋白
JP2010505435A (ja)	2006-10-11	2010-02-25	アブリンクスエン．ヴェー．	本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
WO2009026638A1 (en)	2007-08-31	2009-03-05	Melbourne Health	Marine-animal derived therapeutic and diagnostic agents for hepatitis b
US8524863B2 (en) *	2008-10-06	2013-09-03	Commonwealth Scientific And Industrial Research Organisation	Amyloid-beta peptide crystal structure
BRPI0920810A2 (pt) *	2008-10-07	2015-12-22	Zap Holdings Ltd	sincronização de bancos de dados relacionais com cubos de olap
US8496933B2 (en) *	2009-11-04	2013-07-30	Laboratorios Silanes, S.A. De C.V.	VHNAR anti-cytokine domains
US20140154241A1 (en) *	2010-12-03	2014-06-05	Cyclogenix Ltd	Binding peptides i
WO2013167883A1 (en)	2012-05-07	2013-11-14	The University Court Of The University Of Aberdeen	Single domain binding molecule
CN103031304A (zh) *	2012-12-27	2013-04-10	苏州大学	一种微小rna用于调控b7-h2基因表达
EP3683312B1 (en)	2013-04-23	2022-09-07	Elasmogen Limited	Synthetic library of specific binding molecules

2014
- 2014-04-23 EP EP19208141.2A patent/EP3683312B1/en active Active
- 2014-04-23 DK DK14718999.7T patent/DK2989203T3/da active
- 2014-04-23 WO PCT/EP2014/058276 patent/WO2014173975A1/en not_active Ceased
- 2014-04-23 EP EP14718999.7A patent/EP2989203B1/en active Active
- 2014-04-23 KR KR1020157033430A patent/KR102320189B1/ko active Active
- 2014-04-23 BR BR112015026729A patent/BR112015026729A2/pt not_active Application Discontinuation
- 2014-04-23 BR BR112015026716A patent/BR112015026716A2/pt not_active IP Right Cessation
- 2014-04-23 WO PCT/EP2014/058251 patent/WO2014173959A2/en not_active Ceased
- 2014-04-23 US US14/785,975 patent/US10472410B2/en active Active
- 2014-04-23 KR KR1020157033307A patent/KR20160010466A/ko not_active Withdrawn
- 2014-04-23 CA CA2909921A patent/CA2909921C/en active Active
- 2014-04-23 EP EP14720559.5A patent/EP2989204B1/en active Active
- 2014-04-23 CA CA2909923A patent/CA2909923A1/en not_active Abandoned
- 2014-04-23 AU AU2014257549A patent/AU2014257549B2/en active Active
- 2014-04-23 CN CN201480035865.XA patent/CN105492610B/zh active Active
- 2014-04-23 JP JP2016509455A patent/JP6591964B2/ja active Active
- 2014-04-23 RU RU2015146419A patent/RU2015146419A/ru not_active Application Discontinuation
- 2014-04-23 JP JP2016509450A patent/JP6616284B2/ja active Active
- 2014-04-23 RU RU2015146418A patent/RU2015146418A/ru not_active Application Discontinuation
- 2014-04-23 CN CN201480035842.9A patent/CN105531370A/zh active Pending
- 2014-04-23 AU AU2014257565A patent/AU2014257565A1/en not_active Abandoned
- 2014-04-23 US US14/786,074 patent/US10202438B2/en active Active
2019
- 2019-02-11 US US16/271,959 patent/US11459377B2/en active Active
- 2019-07-18 AU AU2019206064A patent/AU2019206064A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2014173959A2 (en)	2014-10-30
KR102320189B1 (ko)	2021-11-03
JP2016524592A (ja)	2016-08-18
EP2989204A1 (en)	2016-03-02
AU2014257549A1 (en)	2015-11-26
EP2989204B1 (en)	2019-03-20
WO2014173975A1 (en)	2014-10-30
US20160068600A1 (en)	2016-03-10
JP2016524463A (ja)	2016-08-18
US10202438B2 (en)	2019-02-12
JP6616284B2 (ja)	2019-12-04
CA2909921A1 (en)	2014-10-30
BR112015026729A2 (pt)	2017-09-05
RU2015146418A3 (da)	2018-05-07
CN105531370A (zh)	2016-04-27
EP3683312A3 (en)	2020-09-16
WO2014173959A3 (en)	2015-01-29
KR20160010466A (ko)	2016-01-27
US11459377B2 (en)	2022-10-04
JP6591964B2 (ja)	2019-10-16
US20160176951A1 (en)	2016-06-23
RU2015146418A (ru)	2017-05-26
BR112015026716A2 (pt)	2017-09-05
AU2019206064A1 (en)	2019-08-08
AU2014257549B2 (en)	2019-04-18
KR20160015220A (ko)	2016-02-12
RU2015146419A (ru)	2017-05-26
EP2989203A2 (en)	2016-03-02
EP3683312A2 (en)	2020-07-22
US10472410B2 (en)	2019-11-12
CN105492610A (zh)	2016-04-13
US20200002403A1 (en)	2020-01-02
AU2014257565A1 (en)	2015-11-26
EP3683312B1 (en)	2022-09-07
CA2909921C (en)	2022-12-06
CA2909923A1 (en)	2014-10-30
EP2989203B1 (en)	2019-11-13
CN105492610B (zh)	2020-08-25

Publication	Publication Date	Title
IL285521A (en)	2021-09-30	Assays for single molecule detection
DK2970464T3 (da)	2020-08-03	Anti-lag-3-bindende proteiner
HUE032902T2 (hu)	2017-11-28	Kromatográfiás közeg
LT3060041T (lt)	2021-03-25	Prostaciklino junginiai
FI20135770L (fi)	2015-01-13	Prosessi hiilivetyjen valmistamiseksi
DK2970336T3 (da)	2017-11-13	Tetrahydropyrrolothiazinforbindelser
DK3736291T5 (da)	2024-08-26	Anti-FCRH5-antistoffer
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3027615T3 (da)	2021-10-25	Antiinfektionsforbindelser
FI20136031A7 (fi)	2015-04-18	Prosessi hiilivetyjen valmistamiseksi
EP2954567A4 (en)	2016-10-05	PHOSPHOR LAYERS
DK3068800T3 (da)	2019-10-21	FcRn-specifikke antistoffer
DK3055332T3 (da)	2019-12-09	Anti-folr1-immunkonjugat-doseringsregimer
IL240597A0 (en)	2015-09-24	Ligand binding molecules and uses thereof
DK3065774T3 (da)	2021-08-23	Anti-CCL17-antistoffer
IL240904A0 (en)	2015-10-29	Azetidinyloxyphenylpyrrolidine compounds
EP2977504A4 (en)	2016-08-24	DRY
HRP20180618T1 (hr)	2018-07-13	Spojevi fluorfenilpirazola
EP2946304A4 (en)	2016-09-07	VERTICALLY HISTORIZED CLIENT SERVER ARCHITECTURE
LT3052625T (lt)	2021-12-10	Notch 1 specifinės sirnr molekulės
EP2966216A4 (en)	2016-09-28	DRY
UA28910S (uk)	2015-02-25	Степлер
ITMI20130606A1 (it)	2014-10-13	Composti naftoeterodiazolici disostituiti
UA26448S (uk)	2014-02-25	Степлер
UA26335S (uk)	2014-02-10	Степлер